Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Position Increased by Steamboat Capital Partners LLC

Steamboat Capital Partners LLC lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 43.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 249,751 shares of the biopharmaceutical company’s stock after acquiring an additional 75,890 shares during the quarter. Halozyme Therapeutics accounts for about 3.7% of Steamboat Capital Partners LLC’s investment portfolio, making the stock its 8th largest holding. Steamboat Capital Partners LLC’s holdings in Halozyme Therapeutics were worth $11,941,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of HALO. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $52.02 on Friday. The company’s fifty day moving average price is $60.69 and its 200-day moving average price is $55.94. The firm has a market capitalization of $6.41 billion, a price-to-earnings ratio of 15.17, a PEG ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business’s revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.79 EPS. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This trade represents a 5.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock valued at $1,276,552 in the last quarter. Insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HALO shares. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 7th. Benchmark cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Leerink Partners cut shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price on the stock. in a research note on Tuesday, May 13th. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Finally, Morgan Stanley cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $73.00 to $62.00 in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.